Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224802 · ClinicalTrials.gov registry record
Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 372
- Enrollment target
NCT07224802 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 372 participants.
The verdict
NCT07224802 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 372 participants
- Enrollment target
Study Summary
Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery. Reliable preoperative detection of such lesions remains an unmet clinical need. The EXELiM study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to accurately identify PDAC patients at high risk of occult liver metastasis before surgery. By integrating machine learning with multi-institutional plasma exosome profiling, this study seeks to enable biology-driven patient stratification and guide treatment sequencing toward precision oncology.
Interventions
- DIAGNOSTIC_TEST EXELiM assay (qRT-PCR validation)
- DIAGNOSTIC_TEST EXELiM small RNA sequencing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-02-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224802
The ClinicalTrials.gov registry entry for NCT07224802 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EXELiM assay (qRT-PCR validation) is the first listed.
NCT07224802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07224802 about?
NCT07224802 is a clinical study titled "Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting". Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery. Reliable preoperative detection of such lesions remains an unmet clinical need. The EXELiM ...
What is the current status of trial NCT07224802?
This trial is currently completed. The enrollment target is 372 participants. The study started on 2024-06-21. Estimated completion is 2026-02-18.
What interventions are being tested in trial NCT07224802?
The interventions under investigation include: EXELiM assay (qRT-PCR validation) (DIAGNOSTIC_TEST), EXELiM small RNA sequencing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07224802?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.